Truist Financial Sticks to Its Buy Rating for IQVIA Holdings (IQV)

Truist Financial analyst Jailendra Singh reiterated a Buy rating on IQVIA Holdings today and set a price target of $245.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Singh is an analyst with an average return of -17.2% and a 31.60% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Icon, and IQVIA Holdings.

In addition to Truist Financial, IQVIA Holdings also received a Buy from TipRanks – PerPlexity’s PerPlexity Medical – Diagnostics and Research in a report issued on February 17. However, on the same day, TipRanks – Anthropic reiterated a Hold rating on IQVIA Holdings (NYSE: IQV).

Based on IQVIA Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.36 billion and a net profit of $514 million. In comparison, last year the company earned a revenue of $3.96 billion and had a net profit of $437 million

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IQV in relation to earlier this year. Most recently, in December 2025, Ari Bousbib, the Chairman, CEO & President of IQV sold 36,564.00 shares for a total of $8,132,930.52.